Skip to main content
. 2014 Nov 1;6(5):1178–1189. doi: 10.4161/mabs.32114

Figure 8.

Figure 8.

Selectivity was evaluated in the human PK prototype assay to determine if there were any significant recovery differences from human serum matrix across the three test products. Each of the test products were spiked into 6 individual normal human serum donors at the assay LLOQ (50ng/mL), and recovery of the three test products across donors were all within ± 11% of nominal. There were no matrix effects observed in human serum with the biosimilar, FDA-licensed, or EU-authorized reference products.